Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Hepatitis B virus (HBV) infection is contagious with transmissiobn vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir. All were tested for the presence of hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), serum alanine amino transferase (ALT) level and HBV DNA load before and after treatment with ADV. In all samples, resistance to lamivudine and ADV was tested with real time PCR. Among seventy patients with chronic hepatitis B infection, 18 (25.7%) were resistant to LAM and 8 (11.4%) were resistant to ADV. Only one patient was negative for the presence of HBS-Ag (5.6%) and two were negative for HBe-Ag (11.1%). In this study we used a new method (ALLGIO probe assay) that has high sensitivity in detection of adefovir resistance mutants, which we recommend to other researchers. Mutant strains of the YMDD motif of HBV polymerase can be found in some patients under treatment with lamivudine and ADV. ADV has been demonstrated to be efficient in patients with lamivudine resistant HBV.

Keywords

References

  1. Chang MS, SK Olsen, Pichardo EM, et al (2012). Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl, 18, 834-8. https://doi.org/10.1002/lt.23429
  2. Chen CH, CM Lee, Tung WC, et al (2010). Evolution of fulllength HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol, 52, 478-85. https://doi.org/10.1016/j.jhep.2010.01.006
  3. Foroutan SM, A Zarghi, Shafaati A, et al (2011). Rapid high-performance liquid chromatographic method for determination of adefovir in plasma using UV detection: application to pharmacokinetic studies. Arzneimittelforschung, 61, 477-80. https://doi.org/10.1055/s-0031-1296230
  4. Hosaka T, F Suzuki, Kobayashi M, et al (2010). Development of HCC in patients receiving adefovir dipivoxil for lamivudineresistant hepatitis B virus mutants. Hepatol Res, 40, 145-52. https://doi.org/10.1111/j.1872-034X.2009.00582.x
  5. Hu Y, WL Zhang, Xie SL, et al (2012). An improved reverse dot hybridization for simple and rapid detection of adefovir dipivoxil-resistant hepatitis B virus. Genet Mol Res, 11, 53-60. https://doi.org/10.4238/2012.January.9.6
  6. Husic-Selimovic A, Z Vukobrat-Bijedic, Bevanda M, et al (2012). Diagnosis and treatment of chronic viral hepatitis B and C: doctrinary approach. Med Arh, 66, 56-69. https://doi.org/10.5455/medarh.2012.66.s56-s68
  7. Inoue J, Y Ueno, Wakui Y, et al (2011). Four-year study of lamivudine and adefovir combination therapy in lamivudineresistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat, 18, 206-15. https://doi.org/10.1111/j.1365-2893.2010.01301.x
  8. Jamnikar CU, Toplak I (2012). Development of a real-time RTPCR assay with TaqMan probe for specific detection of acute bee paralysis virus. J Virol Methods, 184, 63-8. https://doi.org/10.1016/j.jviromet.2012.05.010
  9. Jayakumar R, YK Joshi, Singh S, et al (2012). Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of Lamivudine and adefovir. J Lab Physicians, 4, 10-6. https://doi.org/10.4103/0974-2727.98664
  10. Jeon JW, HP Shin, Lee JI, et al (2012). Efficacy of entecavir and adefovir combination therapy for patients with lamivudineand entecavir-resistant chronic hepatitis B. Dig Dis Sci, 57, 1358-65. https://doi.org/10.1007/s10620-011-1988-0
  11. Jiang H, J Wang, Zhao W, et al (2012). Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis, 4, 450-6.
  12. Kim JH, YK Jung, Joo MK, et al (2010). Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci, 25, 257-64. https://doi.org/10.3346/jkms.2010.25.2.257
  13. Lim SG, Aung MO, Mak B, et al. (2011). Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. J Clin Gastroenterol, 45, 818-23. https://doi.org/10.1097/MCG.0b013e318214ab5d
  14. Liu H, Mao R, Fan L, et al (2011). Detection of lamivudine-or adefovir-resistant hepatitis B virus mutations by a liquid array. J Virol Methods, 175, 1-6. https://doi.org/10.1016/j.jviromet.2011.04.005
  15. Liu YC, WL Zhang, Hu Y, et al (2010). Detection of HBV resistant mutations related to lamivudine, adefovir and entecavir by reverse hybridization technique. Zhonghua Gan Zang Bing Za Zhi, 18, 414-8.
  16. Malekpour R, HR Mollaie (2012). Detection of HBV Resistance to Lamivudine in Patients with Chronic Hepatitis B, Using Zip Nucleic Acid Probes, Kerman,Southeast of Iran. Asian Pac J Cancer Prev, 13, 1-4. https://doi.org/10.7314/APJCP.2012.13.1.001
  17. Minde Z, Yimin M, Guangbi Y, et al (2012). Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int, 32, 137-46. https://doi.org/10.1111/j.1478-3231.2011.02641.x
  18. Miszczycha SD, Ganet S, Duniere L, et al (2012). Novel realtime PCR method to detect escherichia coli O157:H7 in raw milk cheese and raw ground meat. J Food Prot, 75, 1373-81. https://doi.org/10.4315/0362-028X.JFP-11-498
  19. Osiowy C, Villeneuve JP, Heathcote EJ, et al (2006). Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol, 44, 1994-7. https://doi.org/10.1128/JCM.02477-05
  20. Patterson SJ, George J, Strasser SI, et al (2011). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut, 60, 247-54. https://doi.org/10.1136/gut.2010.223206
  21. Saah AJ, DW Haas, DiNubile MJ, et al (2003). Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. J Infect Dis, 187, 1157-62. https://doi.org/10.1086/368287
  22. Segovia MC, Chacra W, Gordon SC, et al (2012). Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother, 13, 245-54. https://doi.org/10.1517/14656566.2012.649727
  23. Tseng KC, PN Cheng, Wu IC, et al (2009). HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy. Hepatogastroenterology, 56, 813-8.
  24. Veldhuijzen IK, R Wolter, Rijckborst V, et al (2012). Identification and treatment of chronic hepatitis B in Chinese migrants: Results of a project offering on-site testing in Rotterdam, The Netherlands. J Hepatol, 12, 430-6.
  25. Wang YZ, JH Xiao, Ruan LH, et al (2009). Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clin Chim Acta, 408, 70-4. https://doi.org/10.1016/j.cca.2009.07.016
  26. Wu DS, JZ Shen, Shen SF, Wu XM (2010). The establishment and evaluation of diagnostic accuracy of AllGlo(TM) probebased techniques for invasive aspergillosis. Zhonghua Nei Ke Za Zhi, 49, 142-5.
  27. Yoshida S, S Hige, Yoshida M, et al (2008). Quantification of lamivudine-resistant hepatitis B virus mutants by typespecific TaqMan minor groove binder probe assay in patients with chronic hepatitis B. Ann Clin Biochem, 45, 59-64. https://doi.org/10.1258/acb.2007.006219
  28. Zhao WF, YL Shao, Chen LY, et al (2010). Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application. World J Gastroenterol, 16, 1267-73. https://doi.org/10.3748/wjg.v16.i10.1267
  29. Zou J, B Di, Zhang J, et al (2009). Determination of adefovir by LC-ESI-MS-MS and its application to a pharmacokinetic study in healthy Chinese volunteers. J Chromatogr Sci, 47, 889-94. https://doi.org/10.1093/chromsci/47.10.889

Cited by

  1. RNAi and miRNA in Viral Infections and Cancers vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7045